Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28362475 | 0.83 | AHR (0.44) | AHRNR3C1PGRNR3C2AR | |
| SCHEMBL593512 | 0.79 | AHR (0.50) | AHRNR3C1PGRNR3C2AR | |
| SCHEMBL14256041 | 0.77 | AHR (0.42) | AHRNR3C1PGRNR3C2AR | |
| Methane SCHEMBL27929614 | 0.77 | AHR (0.48) | AHRNR3C1PGRNR3C2AR | |
| SCHEMBL1452618 | 0.76 | AHR (0.47) | AHRNR3C1PGRNR3C2AR | |
| SCHEMBL21334962 | 0.75 | AHR (0.32) | AHR | |
| SCHEMBL8040464 | 0.75 | AHR (0.50) | AHRNR3C1PGRNR3C2AR | |
| SCHEMBL2399846 | 0.75 | AHR (0.50) | AHRNR3C1PGRNR3C2AR | |
| SCHEMBL29869958 | 0.75 | AHR (0.50) | AHRNR3C1PGRNR3C2AR | |
| SCHEMBL2260333 | 0.75 | AHR (0.50) | AHRNR3C1PGRNR3C2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| US-11833122-B2 | Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2023-12-05 | — | — | US | disclosed |
| US-20220177462-A1 | SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2022-06-09 | — | — | US | disclosed |
| US-11014921-B2 | Therapeutic compounds and methods of use thereof | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2021-05-25 | — | — | US | disclosed |
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9102625-B2 | Nicotinamides as JAK kinase modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014921-B2 | Therapeutic compounds and methods of use thereof | CD47, C3AR1, HLA-DRB1 | AHR 3582/4885NR3C1 168/4885PGR 2391/4885 |
| US-20220177462-A1 | SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | AHR 2564/4885NR3C1 1534/4885PGR 2313/4885 |
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | AHR 1325/4885NR3C1 3222/4885PGR 1477/4885 |
| US-11833122-B2 | Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases | KEAP1, GOT2, COL1A1 | AHR 76/4885NR3C1 2355/4885PGR 4029/4885 |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | UBQLN1, PSMB1, UBQLN2 | AHR 382/4885NR3C1 2097/4885PGR 2707/4885 |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | AHR 1325/4885NR3C1 3222/4885PGR 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.